Seelos Therapeutics Analyst Ratings
Seelos Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/21/2023 | 396.34% | Benchmark | $4 → $1 | Maintains | Speculative Buy |
| 09/21/2023 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 09/21/2023 | — | Cantor Fitzgerald | Downgrades | Overweight → Neutral | |
| 08/22/2023 | 892.68% | Cantor Fitzgerald | → $2 | Reiterates | Overweight → Overweight |
| 08/15/2023 | 892.68% | Cantor Fitzgerald | → $2 | Reiterates | Overweight → Overweight |
| 06/23/2023 | 892.68% | Cantor Fitzgerald | → $2 | Reiterates | Overweight → Overweight |
| 06/23/2023 | 1885.36% | Benchmark | $4 → $4 | Reiterates | Speculative Buy → Speculative Buy |
| 05/16/2023 | 892.68% | Cantor Fitzgerald | $3 → $2 | Maintains | Overweight |
| 05/15/2023 | 1885.36% | BTIG | $11 → $4 | Maintains | Buy |
| 03/30/2023 | 5359.73% | BTIG | → $11 | Maintains | Buy |
| 03/24/2023 | 1885.36% | Benchmark | $6 → $4 | Maintains | Buy |
| 02/13/2023 | 5856.07% | BTIG | $12 → $12 | Maintains | Buy |
| 04/28/2022 | 5856.07% | BTIG | → $12 | Maintains | Buy |
| 03/14/2022 | 1885.36% | B. Riley Securities | $6 → $4 | Maintains | Buy |
| 03/08/2022 | 1389.02% | Cantor Fitzgerald | $5 → $3 | Maintains | Overweight |
| 09/27/2021 | 3870.72% | Roth Capital | $2.5 → $8 | Upgrades | Neutral → Buy |
| 08/10/2021 | 1140.85% | Roth Capital | $4 → $2.5 | Maintains | Neutral |
| 07/01/2021 | 3870.72% | Guggenheim | → $8 | Initiates Coverage On | → Buy |
| 06/01/2021 | 4863.39% | Cantor Fitzgerald | → $10 | Initiates Coverage On | → Overweight |
| 03/30/2021 | 7345.09% | B. Riley Securities | → $15 | Initiates Coverage On | → Buy |
| 03/12/2021 | 6848.75% | BTIG | → $14 | Initiates Coverage On | → Buy |
| 11/18/2019 | 892.68% | HC Wainwright & Co. | $4 → $2 | Maintains | Buy |
| 11/14/2019 | — | Benchmark | Initiates Coverage On | → Speculative Buy | |
| 05/14/2019 | — | Roth Capital | Initiates Coverage On | → Buy | |
| 05/10/2019 | 1885.36% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年09月21日 | 396.34% | 基準 | $4→$1 | 維護 | 投機性購買 |
| 2023年09月21日 | - | 古根海姆 | 評級下調 | 購買→中性 | |
| 2023年09月21日 | - | 康託·菲茨傑拉德 | 評級下調 | 超重→中性 | |
| 2023年08月22日 | 892.68% | 康託·菲茨傑拉德 | →$2 | 重申 | 超重→超重 |
| 2023年08月15日 | 892.68% | 康託·菲茨傑拉德 | →$2 | 重申 | 超重→超重 |
| 2023/06/23 | 892.68% | 康託·菲茨傑拉德 | →$2 | 重申 | 超重→超重 |
| 2023/06/23 | 1885.36% | 基準 | $4→$4 | 重申 | 投機性買入→投機性買入 |
| 2023年05月16日 | 892.68% | 康託·菲茨傑拉德 | $3→$2 | 維護 | 超重 |
| 2023年05月15日 | 1885.36% | BTIG | $11→$4 | 維護 | 買 |
| 03/30/2023 | 5359.73% | BTIG | →$11 | 維護 | 買 |
| 03/24/2023 | 1885.36% | 基準 | $6→$4 | 維護 | 買 |
| 02/13/2023 | 5856.07% | BTIG | $12→$12 | 維護 | 買 |
| 04/28/2022 | 5856.07% | BTIG | →$12 | 維護 | 買 |
| 03/14/2022 | 1885.36% | B.萊利證券 | $6→$4 | 維護 | 買 |
| 03/08/2022 | 1389.02% | 康託·菲茨傑拉德 | $5→$3 | 維護 | 超重 |
| 09/27/2021 | 3870.72% | 羅斯資本 | $2.5→$8 | 升級 | 中性→購買 |
| 2021/08/10 | 1140.85% | 羅斯資本 | $4→$2.5 | 維護 | 中性 |
| 07/01/2021 | 3870.72% | 古根海姆 | →$8 | 開始承保 | →購買 |
| 06/01/2021 | 4863.39% | 康託·菲茨傑拉德 | →$10 | 開始承保 | →超重 |
| 03/30/2021 | 7345.09% | B.萊利證券 | →$15 | 開始承保 | →購買 |
| 03/12/2021 | 6848.75% | BTIG | →$14 | 開始承保 | →購買 |
| 2019年11月18日 | 892.68% | HC Wainwright公司 | $4→$2 | 維護 | 買 |
| 2019年11月14日 | - | 基準 | 開始承保 | →投機性買入 | |
| 2019年05月14日 | - | 羅斯資本 | 開始承保 | →購買 | |
| 2019年5月10日 | 1885.36% | HC Wainwright公司 | →$4 | 開始承保 | →購買 |
What is the target price for Seelos Therapeutics (SEEL)?
Seelos治療公司(SEEL)的目標價格是多少？
The latest price target for Seelos Therapeutics (NASDAQ: SEEL) was reported by Benchmark on September 21, 2023. The analyst firm set a price target for $1.00 expecting SEEL to rise to within 12 months (a possible 396.34% upside). 12 analyst firms have reported ratings in the last year.
基準公司於2023年9月21日報道了Seelos治療公司(納斯達克：SEEL)的最新目標價。這家分析公司將目標價定為1美元，預計SEL將在12個月內升至(可能上漲396.34%)。去年有12家分析公司公佈了評級。
What is the most recent analyst rating for Seelos Therapeutics (SEEL)?
Seelos治療公司(SEEL)的最新分析師評級是多少？
The latest analyst rating for Seelos Therapeutics (NASDAQ: SEEL) was provided by Benchmark, and Seelos Therapeutics maintained their speculative buy rating.
西洛斯治療公司(納斯達克代碼：SEEL)的最新分析師評級由Benchmark提供，西洛斯治療公司維持其投機性買入評級。
When is the next analyst rating going to be posted or updated for Seelos Therapeutics (SEEL)?
Seelos治療公司(SEEL)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Seelos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Seelos Therapeutics was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Seelos Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Seelos治療公司的上一次評級是在2023年9月21日提交的，所以你應該預計下一次評級將在2024年9月21日左右的某個時候提供。
Is the Analyst Rating Seelos Therapeutics (SEEL) correct?
分析師對Seelos Treeutics(SEEL)的評級正確嗎？
While ratings are subjective and will change, the latest Seelos Therapeutics (SEEL) rating was a maintained with a price target of $4.00 to $1.00. The current price Seelos Therapeutics (SEEL) is trading at is $0.20, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Seelos治療公司(SEEL)評級保持不變，目標價在4.00美元至1.00美元之間。Seelos治療公司(SEEL)目前的交易價格為0.2美元，超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。